A Phase III Randomized, Partially Double-Blind, Active-Comparator Controlled, Lot-to-Lot Consistnecy Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Health Infants When Given at 2,4, and 6 Months Concomitantly with P

StatusFinished
Effective start/end date1/07/1122/05/15

Funding

  • Merck Co.: $157,200.56

Keywords

  • Biotechnology & Drug Development, Immunology, Infectious Diseases